< Zurück zu den aktuellen Neuigkeiten & Events

Veranstaltungen

OPT Congress – Cambridge

März 2019

Veranstaltungsdatum: 26. März 2019

HGF Patent Director Alison Gallafent will be presenting “siRNA science journey as reflected by the patent literature” at the 4th Annual Oligonucleotide & Precision Therapeautics March 26-28 2019 in Cambridge.

To complement the 4th annual Oligonucleotide Discover and Delivery conference there will also be a 2 day program dedicated to Oligonucleotide CMC and Regulatory Strategies plus two in-depth symposiums focusing on Drug Discovery for Rare Diseases and New Frontiers in Gene Editing and Repair.

The OPT congress brings together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers to provide a unique opportunity to discuss advances in next generation oligonucleotide therapies throughout the drug development process.

Patent Director Alison Gallafent will be presenting “siRNA science journey as reflected by the patent literature”.

Starting with patents that initially reflected manufacturing constraints, moving to patents reflecting greater understanding of chemical modifications, and later product specific patents.  Advantages and potential challenges are associated with patent protection at the different stages of this journey.  Close interaction between Research and Attorney can help to address potential challenges.

Aktuelle Neuigkeiten

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Weiterlesen
Event - 14. Oktober 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Veranstaltungsdetails

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Weiterlesen

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Weiterlesen

HGF hoch platziert im Legal 500 2026

Die Rangliste des Legal 500 UK 2026 wurde veröffentlicht und HGF wurde erneut in mehreren Regionen und Praxisbereichen platziert. HGF ist weiterhin in der Spitzenklasse des britischen PATMA – Markenzeichen …

Weiterlesen

12 Anwälte von HGF als „Managing IP Rising Stars 2025” ausgezeichnet

Wir sind sehr stolz darauf, bekannt geben zu dürfen, dass 12 unserer Anwälte in den aktuellen „Managing IP Rankings” als „Rising Stars” ausgezeichnet wurden! Diese Auszeichnung würdigt die nächste Generation …

Weiterlesen

IP Ingredients: The companies making – and patenting - alt coffee

How do you like your coffee? Frothy or flat? Milky or black? Oat-milk or soy?  How about coffee which isn’t derived from coffee beans? Coffee is the second most traded …

Weiterlesen
Event - 29. September 2025

HGF ist Bronze-Sponsor der LES Pan-European Conference 2025

Wir sind stolz darauf, Bronze-Sponsor der LES Pan-European Conference 2025 zu sein, die vom 29. bis 30. September 2025 im The Hague Marriott Hotel in den Niederlanden stattfindet. Die diesjährige …

Veranstaltungsdetails